Eun Ji Ro
Overview
Explore the profile of Eun Ji Ro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
390
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cho Y, Ro E, Yoon J, Mizutani T, Kang D, Park J, et al.
Nat Commun
. 2020 Oct;
11(1):5321.
PMID: 33087710
5-Fluorouracil (5-FU) remains the first-line treatment for colorectal cancer (CRC). Although 5-FU initially de-bulks the tumor mass, recurrence after chemotherapy is the barrier to effective clinical outcomes for CRC patients....
2.
Ro E, Ryu S, Park E, Ryu J, Byun S, Heo S, et al.
Breast Cancer Res Treat
. 2020 Jun;
182(3):591-600.
PMID: 32529408
Purpose: This study evaluates the oncogenic role of PIBF1 in triple-negative breast cancer (TNBC). TNBC is considered to have a poorer prognosis than other types of breast cancer and is...
3.
Cho Y, Ro E, Yoon J, Kwak D, Cho J, Kang D, et al.
Cell Commun Signal
. 2020 Mar;
18(1):38.
PMID: 32143715
Background: Cancer stem cells (CSCs), the major driver of tumorigenesis, is a sub-population of tumor cells responsible for poor clinical outcomes. However, molecular mechanism to identify targets for controlling CSCs...
4.
Ro E, Cho Y, Jeong W, Park J, Min D, Choi K
Cell Commun Signal
. 2019 Aug;
17(1):88.
PMID: 31362761
Background: Stabilization of RAS is a key event for the hyper-activation of Wnt/β-catenin signaling and activation of cancer stem cell (CSC) in colorectal cancer (CRC). WD Repeat protein 76 (WDR76)...
5.
Jeong W, Park J, Kim W, Ro E, Jeon S, Lee S, et al.
Nat Commun
. 2019 Jan;
10(1):295.
PMID: 30655611
Stability regulation of RAS that can affect its activity, in addition to the oncogenic mutations, occurs in human cancer. However, the mechanisms for stability regulation of RAS involved in their...
6.
Lee S, Cho Y, Cha P, Yoon J, Ro E, Jeong W, et al.
Exp Mol Med
. 2018 Nov;
50(11):1-12.
PMID: 30459318
Drugs targeting the epidermal growth factor receptor (EGFR), such as cetuximab and panitumumab, have been prescribed for metastatic colorectal cancer (CRC), but patients harboring KRAS mutations are insensitive to them...
7.
Lee S, Jeong W, Cho Y, Cha P, Yoon J, Ro E, et al.
EMBO Rep
. 2018 Nov;
19(12).
PMID: 30413483
RAS proteins play critical roles in various cellular processes, including growth and transformation. RAS proteins are subjected to protein stability regulation via the Wnt/β-catenin pathway, and glycogen synthase kinase 3...
8.
Shin W, Lee S, Hwang J, Park J, Cho Y, Ro E, et al.
Exp Mol Med
. 2018 Jun;
50(6):1-10.
PMID: 29884842
Although the development of drugs that control Ras is an emerging topic in cancer therapy, no clinically applicable drug is currently available. We have previously utilized knowledge of the Wnt/β-catenin...
9.
Jeong W, Ro E, Choi K
NPJ Precis Oncol
. 2018 Jun;
2(1):5.
PMID: 29872723
Aberrant activation of the Wnt/β-catenin and RAS-extracellular signal-regulated kinase (ERK) pathways play important roles in the tumorigenesis of many different types of cancer, most notably colorectal cancer (CRC). Genes for...
10.
Cho Y, Cha P, Kaduwal S, Park J, Lee S, Yoon J, et al.
Oncotarget
. 2016 Nov;
7(49):81727-81740.
PMID: 27835580
APC (80-90%) and K-Ras (40-50%) mutations frequently occur in human colorectal cancer (CRC) and these mutations cooperatively accelerate tumorigenesis including metastasis. In addition, both β-catenin and Ras levels are highly...